SCHEDULE: Affinity Asset Advisors Discloses 9.99% Stake in NextCure
Beneficial Ownership Disclosure
Affinity Asset Advisors and Michael Cho have disclosed a 9.99% beneficial ownership stake in NextCure, Inc., including shares from warrants.
Summary
- Affinity Asset Advisors, LLC and Michael Cho (Reporting Persons) beneficially own 348,607 shares of NextCure, Inc. common stock.
- This represents approximately 9.99% of the company's outstanding common stock.
- The ownership includes 101,313 shares issuable upon the exercise of warrants.
- The warrants are subject to a beneficial ownership limitation of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to their exercise.
- The percentage is calculated based on 3,489,563 shares outstanding as of October 31, 2025, which includes shares from a private placement and warrant exercises.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of NextCure, Inc.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive development, as a significant institutional investment often indicates a vote of confidence in the company's value and future potential.
Positives
- A significant institutional investor, Affinity Asset Advisors, LLC, and its managing member, Michael Cho, have taken a substantial 9.99% stake in NextCure, Inc., indicating confidence in the company.
- The investment includes warrants, suggesting a long-term perspective and potential for increased ownership.
Future Outlook
The filing does not provide any forward-looking statements or guidance regarding NextCure, Inc.'s future performance or strategic direction.
Industry Context
StockSavvy.ai notes that a significant stake by an investment advisor like Affinity Asset Advisors can signal increased institutional interest in NextCure, Inc., potentially reflecting a positive view on the company's long-term prospects within its sector.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor may instill greater confidence and potentially attract further investment, positively impacting share price.
- Company Management: A large institutional holder may exert influence through voting power, though the filing states the stake is not for changing control.
Key Dates
| Date | Description |
|---|---|
| 2025-10-31 | Date used for calculating total outstanding shares (3,489,563 shares). |
| 2025-11-14 | Date of private placement where 708,428 shares were issued. |
| 2025-11-17 | Date of Form 8-K filing reporting the private placement. |
| 2025-12-19 | Date of Prospectus Supplement filing with the SEC. |
| 2025-12-31 | Date as of which the Fund and Adviser beneficially owned 348,607 shares with shared voting and dispositive power. |
| 2026-01-22 | Date of event which requires the filing of this statement. |
| 2026-01-29 | Date of signing the Schedule 13G and Joint Filing Agreement. |
Recommendation
holdWhile the disclosure of a significant institutional stake is generally positive, a Schedule 13G filing primarily provides ownership information without detailing the underlying investment thesis or company-specific operational updates. Investors should hold and await further company-specific news or financial reports to make a more informed decision, as this filing alone does not provide enough fundamental data to warrant a 'buy' or 'sell' recommendation.
Keywords
NextCure Inc, Affinity Asset Advisors, Michael Cho, Schedule 13G, beneficial ownership, common stock, warrants, institutional investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.